

Resource Summary Report

Generated by [PRECISE-TBI](#) on Aug 10, 2026

Covaris: E220evolution Focused ultrasonicator

RRID:SCR_019817

Type: Tool

Proper Citation

Covaris: E220evolution Focused ultrasonicator (RRID:SCR_019817)

Resource Information

URL: <https://covaris.com/products/afa-ultrasonication/e220evolution/>

Proper Citation: Covaris: E220evolution Focused ultrasonicator (RRID:SCR_019817)

Description: Focused ultrasonicator that enables multi sample, batch preparation, capable of processing wide range of sample types and volumes.

Resource Type: instrument resource

Keywords: Covaris, Focused Ultrasonicator, Covaris, Instrument Equipment, USEDit,

Availability: Commercially available

Specification URL: https://raw.githubusercontent.com/SciCrunch/RRID-Instruments/main/PDF/SCR_019817.pdf

Resource Name: Covaris: E220evolution Focused ultrasonicator

Resource ID: SCR_019817

Alternate IDs: Model_Number_E220_Evolution

Alternate URLs: https://www.covaris.com/wp/wp-content/uploads/resources_pdf/M020001.pdf

Record Creation Time: 20220129T080347+0000

Record Last Update: 20260808T190141+0000

Ratings and Alerts

No rating or validation information has been found for Covaris: E220evolution Focused ultrasonicator.

No alerts have been found for Covaris: E220evolution Focused ultrasonicator.

Data and Source Information

Source: [SciCrunch Registry](#)

Usage and Citation Metrics

We found 4 mentions in open access literature.

Listed below are recent publications. The full list is available at [PRECISE-TBI](#) .

Brotsky AL, et al. (2026) Combination Therapy with Copanlisib and Niraparib in Patients with Recurrent Endometrial and Ovarian Cancer (COPANIRA): Efficacy, Toxicity, and Translational Insights. Clinical cancer research : an official journal of the American Association for Cancer Research, 32(7), 1234.

Campbell KM, et al. (2026) Cellular neighborhoods govern antitumor T-cell infiltration following anti-CTLA-4 in melanoma with primary resistance to anti-PD-1. Cancer discovery.

Klemm N, et al. (2025) The Prolonged Half-Life of the p53 Missense Variant R248Q Promotes Accumulation and Heterotetramer Formation with Wild-Type p53 to Exert the Dominant-Negative Effect. Cancer research, 85(11), 1978.

Van Laethem JL, et al. (2025) CD40 agonist mitazalimab with mFOLFIRINOX in untreated metastatic pancreatic cancer: Biomarkers associated with outcomes from OPTIMIZE-1. Cell reports. Medicine, 6(10), 102407.